- Home
- TVIV vs ARMP Comparison
TVIV vs ARMP Comparison
Compare TVIV & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVIV | ARMP |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.5M | 199.7M |
| IPO Year | 2025 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TVIV | ARMP |
|---|---|---|
| Price | $9.96 | $3.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 40.4K | ★ 87.9K |
| Earning Date | N/A | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $2.75 |
| 52 Week High | $9.99 | $14.98 |
Technical Indicators
Market Signals| Indicator | TVIV | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 43.20 |
| Support Level | $9.85 | $2.75 |
| Resistance Level | $9.97 | $3.96 |
| Average True Range (ATR) | 0.01 | 0.35 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 40.00 | 32.69 |
Price Performance
Historical ComparisonAbout TVIV Texas Ventures Acquisition IV Corp Class A Ordinary Shares
Texas Ventures Acquisition IV Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.